Attract-1 was a pivotal study of ASA404 in previously untreated, advanced NSCLC. Patients were randomised 1:1 to receive either ASA404 plus chemotherapy (carboplatin/paclitaxel) or a placebo plus chemotherapy
Progen said that Sue MacLeman has international senior management and leadership experience in product development and commercialisation in the biotechnology and pharmaceutical sector. Ms MacLeman is also a
The filing of the IND follows a successful Pre-IND meeting with the FDA, during which guidance was provided to the company regarding the basis of approval and the
The new unit will comprise three manufacturing clean rooms, and microbiological and chemical laboratories. Vetter said that the facility features a fully automated production line that automates processes
The transaction with Biovail includes a purchase price of $10m and additional payments of up to $1.5m based upon defined clinical development milestones. The agreement entails the transfer
Monitor for Hire said that through its proprietary web-based platform it offers speed, efficiency and cost savings for its clients. Using this platform, clients can connect with Monitors
Reportedly, team leader Michael Krainer and his colleagues are expected to concentrate primarily on tumors diagnosed late or those which recur after surgical interventions, and which do not
EntreMed has posted total revenues of $1.61m, compared to $3.97m for the same period in 2008. For the fiscal year 2009, EntreMed has posted a net loss of
Pursuant to the agreements, Parenteral is authorised to register, supply and distribute Sinovac’s Anflu (seasonal influenza vaccine) and Panflu1 (H1N1 vaccine) to the government of India and private
The patent identifies and protects peptides that were discovered using MDRNA’s proprietary Trp Cage Phage Display Library and describes targeting peptides that demonstrate high binding affinity to, and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.